Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_433b3349f6e826ebe046fc581a48aab6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_63391f645355cd51186dbd0f19def634 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2017-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df7ef8cd4e7c9b027797894e19c4f602 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fd3f6598f8edf13af80012540de8348 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2b40c91778cb64b5f5e3787d9c2e7a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fe5a9f07e224866a8adbe57d96d76ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b1c0dbb77fb69b58af877884e57f1d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdbfbd39fe1bb723183b46b77a6759b1 |
publicationDate |
2019-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2019038591-A1 |
titleOfInvention |
Use of a fasting mimicking diet to enhance the efficacy of antiestrogens in cancer |
abstract |
A compound having antiestrogenic activity is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting mimicking diet for a period of 24-190 hours while the patient is being treated with the compound having antiestrogenic activity, which can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor downregulator (SERD) or an aromatase inhibitor (AI). |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021126968-A1 |
priorityDate |
2016-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |